Pangaea Oncology (XMAD:PANG) FFO


XMAD:PANG Pangaea Oncology SA XMAD:PANG
67 GF Score
Price €1.51
GF Value €2.14
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology FFO?

FFO (Funds from operations) only applies to REITs.

XMAD:PANG
67GF Score
Pangaea Oncology SA XMAD:PANG
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.51 is trading 29.4% below its estimated GF Value™ of €2.14. GuruFocus considers Pangaea Oncology to be Modestly Undervalued.

Key valuation signals for XMAD:PANG:

  • FFO:
  • GF Value™: €2.14 vs. price of €1.51 (29.4% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
67GF Score

Get the complete analysis for XMAD:PANG

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€2.14
GF Value